David E. Lazar - 22 Apr 2026 Form 4 Insider Report for Quantum Cyber N.V. (QUCY)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: QUCY
Reported as of: 22 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Apr 2026, 17:39:45 UTC
Prior SEC filing: 02 Apr 2026
Next SEC filing: 01 May 2026
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for Quantum Cyber N.V. (QUCY) on 28 Apr 2026.

Key facts

This page summarizes David E. Lazar's Form 4 filing for Quantum Cyber N.V. (QUCY).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Apr 2026, 17:39.

Change

Previous filing in this sequence was filed on 02 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QUCY holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 22 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QUCY transaction Derivative

Series D Preferred Shares

Award

Transaction value
Shares: +1,000,000
Change %
Price: $1.50^*
Shares after: 1,000,000
Date: 22 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 225,000,000
Exercise price
Footnotes: F2, F3, F4, F5

QUCY transaction Derivative

Series E Preferred Shares

Award

Transaction value
Shares: +1,000,000
Change %
Price: $1.50^*
Shares after: 1,000,000
Date: 22 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 225,000,000
Exercise price
Footnotes: F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

No ordinary shares are beneficially owned.

Footnote F2

As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000.

Footnote F3

On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares.

Footnote F4

The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration.

Footnote F5

Each class of Preferred Stock is perpetual and therefore has no expiration date.